



Stratatech Corporation
505 S. Rosa Road, Suite 170
Madison, WI 53719
608-441-2750
fax – 608-441-2757
www.stratatechcorp.com

Rep. Tammy Baldwin
U.S. House of Representatives
2446 Rayburn Building
Washington, D.C. 20515

April 2, 2009

Dear Rep. Baldwin:

Thank you very much for your continuing interest in Stratatech Corporation. We are particularly grateful for your support of our clinical trial project, which will evaluate the efficacy of StrataGraft[®] tissue in both accelerating healing and reducing infection of blast-induced complex skin defects. The project is ready for immediate implementation.


As you know, skin loss due to blast-induced burns and trauma is a major medical problem affecting deployed combat personnel. Burns account for approximately five percent of combat casualties sustained in both OIF and OEF and historically have accounted for up to 20 percent of combat casualties. Data collected regarding the diagnosis of wounded marines and sailors following the initial combat phase of OIF suggests that, in addition to burns (3.6% of diagnoses in the population studied), there are open skin wound injuries suffered during combat (42.0% of diagnoses) that could present the same primary and secondary treatment problems. Clinical evaluation and FDA approval of StrataGraft[®] tissue, supported by the proposed study, will benefit active duty military service members by providing a readily available source of pathogen-free, human skin for immediate treatment of blast-induced complex skin defects.

Importantly for the citizens of Wisconsin, the successful completion of this clinical trial and FDA-approval would enable distribution and use of this product for the civilian population, providing an innovative wound treatment option and fulfilling a significant unmet medical need. For example, infected, non-healing skin wounds contribute significantly to morbidity and mortality in individuals with diabetes. In the last three years, the adult prevalence of diabetes in Wisconsin increased more than 27 percent to nearly 420,000. Furthermore more than 1 million adults 20 years and older in Wisconsin have pre-diabetes. The medical and societal costs of non-healing skin wounds in diabetics are enormous and growing. Hospital discharge data indicate that up to 20 percent of all diabetics hospitalized in North America within a given year will experience non-healing skin wounds. Unfortunately, the number of hospital discharges in the United States for diabetes-related amputations has risen in the last decade; approximately 82,000 diabetes-induced lower extremity amputations occur each year. In Wisconsin, diabetes-related hospitalization charges increased nearly 50 percent from 2005 to 2008. In Milwaukee County alone, the 2008 cost of diabetes was a staggering \$870 million.

In addition to the anticipated clinical impact of StrataGraft[®] tissue, this project is expected to create additional, well-paying jobs at Stratatech. The company anticipates hiring a minimum of 35 biotechnology-related personnel to assist with the clinical trial. This number will continue to grow each year. Once the trial is complete and the FDA approval received, we would anticipate hiring more personnel as we ramp up manufacturing of the tissue to commercial scale. We estimate that more than 200 biotechnology and high-tech manufacturing jobs will be created as a result of this project.

Thank you again for your support of Stratatech and this important project. It has the potential to significantly affect not just military and civilian health care, but the Madison-area economy as well.

Sincerely yours,

A handwritten signature in black ink that reads "B. Lynn Allen-Hoffmann". The signature is written in a cursive style with a long horizontal stroke at the end.

B. Lynn Allen-Hoffmann, Ph.D.
Chief Executive Officer and Chief Scientific Officer
Stratatech Corporation